Guidance

NMRS-South: user handbook

Updated 25 August 2023

Introduction

This user handbook is intended for use by laboratories referring samples and cultures to the National Mycobacterium Reference Service (NMRS)-South.

NMRS-South is an accredited constituent reference laboratory of specialised microbiology and laboratories of UK Health Security Agency (UKHSA). With its sister laboratory, the NMRS – Central and North based in Birmingham, it provides mycobacterial reference services to the NHS in England, and works closely with mycobacterial reference services in the devolved administrations.

The principal activities of the unit include:

• provision of a Mycobacterial Reference Service utilising Whole Genome Sequencing (WGS) for identification of Mycobacterium sp isolates
• prediction of drug susceptibility for Mycobacterium tuberculosis (M. tuberculosis (TB)) and determination of relatedness
• investigation of outbreaks of M. tuberculosis

Phenotypic drug susceptibility testing (DST) is carried out for selected M. tuberculosis and non-tuberculosis mycobacteria (NTM) isolates. Extended testing is carried out for M. tuberculosis complex isolates with resistance to first line agents.

The laboratory also offers a primary isolation service, including microscopy and culture, and a Fastrack (polymerase chain reaction (PCR)) service for detection of M. tuberculosis complex and rifampicin resistance.

NMRS-South provides information and advice to clinical and public health teams, assisting in the identification and investigation of TB transmission and actively supporting outbreak investigation and surveillance activity within the UK.

Since January 2018, NMRS-South has utilised WGS for the identification of all mycobacterial isolates and detection of resistance for M. tuberculosis. The laboratory no longer provides MIRU-VNTR typing as WGS provides improved discrimination based on single nucleotide polymorphism (SNP) differences between all sequenced isolates. By implementing WGS within a single management structure across both laboratories in the NMRS for England the new service improves the diagnosis, treatment and public health management of TB and plays a significant role in delivering England’s TB strategy.

NMRS-South understands that it may take some time for users to establish familiarity with report formats; clinical and scientific support is always available from NMRS-South to guide users through the change to WGS.

The WGS service includes:

• identification of mycobacterial cultures
• sensitivity/resistance prediction
• determination of relatedness between M.tuberculosis complex isolates (typing)

Identification of NTM continues to be a core part of our service. We are working to standardise our testing methods and costs across the service, including DST. We are monitoring turnaround times as part of the service, aiming to report full WGS results within 7 working days of the receipt of pure positive cultures.

The unit is a World Health Organization (WHO) Supranational Reference Laboratory for M. tuberculosis DST. Together with centres in Germany, Sweden and Belgium, it co-ordinates External Quality Assurance (EQA) for DST across the EU and non-EU states in the WHO Euro region.

It is also a member of WHO’s Global Laboratory Initiative (GLI) involved with the development of WHO and International Union Against Tuberculosis and Lung Disease (IUATLD) strategies for management of mycobacterial diseases and participates in international EQA schemes receiving samples and dispatching to designated regions.

Ownership and accountability of the user handbook lies with the Laboratory Manager and Clinical Lead for NMRS-South. This is version 13, 21 August 2023, Qpulse MYRUW239.

Contact information

Delivery address

National Mycobacterium Reference Service-South (NMRS-South)

National Infection Service, 61 Colindale Avenue
London
NW9 5EQ

Email nmrs.south@ukhsa.gov.uk

Telephone 020 832 76957

DX address DX 6530016, Colindale NW

Hours of services

Service will be provided between 9am to 5pm, Monday to Friday (excluding Bank holidays).

Establishment of service agreement

Each request referred from a stakeholder to the laboratory for testing is considered to be an agreement under UKHSA terms and conditions of business.

General and clinical enquiries

General results enquiries are initially addressed by our administrative staff who will direct clinical and technical enquiries to the appropriate staff. There is daily cover for clinical and technical issues.

Complex cases are discussed further internally and the advice given will often be a product of this discussion, not just the opinion of the person answering the telephone call. We record the advice given for continuity and must know the identity of both the patient and the caller.

For the NMRS-South pricelist, please contact the laboratory by:

• email: nmrs.south@ukhsa.gov.uk, phe.nrms-south@nhs.net
• telephone: 020 8327 6957, 020 8327 7708

Personnel contact details

Role	Name	Email	Telephone
Clinical Lead	Dr Esther Robinson	esther.robinson@ukhsa.gov.uk	020 8327 7708
Interim Regional Head of Operations, London and South East of England and NMRS-South	Mrs Norah Easy	norah.easy@ukhsa.gov.uk	020 8327 6501
Interim Laboratory Manager	Ms Jana Catalan Riezu	jana.catalanriezu@ukhsa.gov.uk	020 8327 7708
Deputy Laboratory Manager	Mr Jesus Fresno Vara	jesus.fresno@ukhsa.gov.uk	020 8327 7708
Clinical Scientist	Dr Simon Warwick	simon.warwick@ukhsa.gov.uk	020 8327 7596
Quality Manager	Mrs Lucy Taylor	lucy.taylor@ukhsa.gov.uk	020 8327 7708
Training and Development Officer	Ms Vanessa Waite	vanessa.waite@ukhsa.gov.uk	020 8327 7708

If you want to speak to the Laboratory Safety Officer, please contact the Laboratory Manager.

Complaints

Complaints can be submitted by post, email or telephone to the Laboratory Manager and Clinical Lead of NMRS-South. If contacting by email, please also include nmrs.south@ukhsa.gov.uk as a recipient.

The complainant will be initially responded to within 5 working days of the complaint being raised. Full investigations and corrective actions will be applied within 20 working days wherever possible.

Summary of services

NMRS-South provides the following services:

• identification of Mycobacterium spp. isolates (WGS based identification service from liquid or solid culture media provided free to the NHS)
• DST and genotypic resistance prediction for M. tuberculosis complex*
• DST for NTM (phenotypic culture and microtiter plate based testing for clinically significant NTM isolates)
• determination of M. tuberculosis isolate relatedness based on SNP differences determined by WGS, provided free to the NHS and for the support of outbreak investigations, detection of laboratory cross-contamination events and so on
• primary isolation service (including microscopy and culture)
• Fastrack (PCR) service (molecular detection of M. tuberculosis complex and rifampicin resistance in primary specimens only)
• scientific and technical advice
• clinical advice for case and outbreak investigation and management
• archived collection of Mycobacterium isolates for epidemiological analysis
• training
• research and development

* Genotypic drug susceptibility predictions are made for all isolates; however, routine phenotypic susceptibility testing for first line agents is no longer performed – this includes isoniazid, rifampicin, pyrazinamide and ethambutol. If WGS predicts resistance or if WGS data is not sufficiently clear to accurately make a prediction, phenotypic testing of first line agents will be performed. Testing for second and third line agents will be performed for multi-drug resistant (MDR) isolates when clinically indicated.

Further information concerning services or matters of interest is available from UKHSA on GOV.UK

Tests and turnaround times

All turnaround times are dependent upon the receipt of 3mls of pure culture containing sufficient bacteria for analysis; we will attempt to purify contaminated cultures where possible.

Reference service	Description	Turnaround time
WGS-based identification of AFB positive cultures and prediction of sensitivities	DNA sequencing is performed for species identification and prediction of sensitivities: WGS Isoniazid WGS Rifampicin WGS Ethambutol WGS Pyrazinamide WGS Quinolone group WGS Streptomycin WGS Aminoglycosides group	Only cultures received by 9:30am are processed the same day, all other cultures are processed the following day Reported within 7 working days of culture receipt
Phenotypic M. tuberculosis susceptibility
First line antibiotics	Isoniazid, Rifampicin, Ethambutol, Pyrazinamide – not performed routinely (see summary of NMRS-South services)	Reported within 40 working days of culture receipt
Reserve antibiotics	Moxifloxacin, Levofloxacin, Amikacin, Kanamycin, Prothionamide, Capreomycin, Linezolid	Reported within 40 working days of request for reserve sensitivities, identification of rifampicin resistance or multidrug-resistant TB (MDRTB) in referred cultures
Additional antibiotics – on clinican’s request only	Delamanid, Clofazimine and Bedaquiline	Referred to emerging bacterial pathogens unit in Italy (see referral of specimens and cultures section below)
NTM susceptibility [note 1]	Rapid growers: Amikacin, Tobramycin, Cefoxitin, Co-trimoxazole, Clarithromycin, Linezolid, Ciprofloxacin, Moxifloxacin, Doxycyline Slow growers: Clarithromycin, Rifampicin, Amikacin, Ciprofloxacin, Doxycycline, Moxifloxacin, Linezolid, Rifabutin, Co-trimoxazole	Rapid growers reported within 35 working days of culture receipt Slow growers reported within 40 working days of culture receipt

[note 1] Testing of further agents can be performed if clinically indicated. Please contact NMRS-South to discuss individual cases.

Primary services turnaround times

Fluorescence microscopy on clinical samples

Reported within one working day of specimen receipt.

Culture of clinical samples on liquid and solid media

Final negative result reported after 30 working days (6 weeks) or 40 working days (8 weeks) for blood and cerebrospinal fluid (CSF) samples.

Note, cultures that are negative at 6 or 8 weeks that were positive on either Fastrack or microscopy are incubated further for a total of 12 weeks. A report is only issued if the culture subsequently becomes positive. A further incubation comment is also added to the report for such cases.

PCR services for clinical samples turnaround times

Rapid detection of M. tuberculosis complex and rifampicin resistance

Clinical samples received by 9:30am are analysed on the same day and results communicated to the sending laboratory within one working day.

A minimum volume of 0.5ml cerebrospinal fluid (not supernatant) is required for Fastrack.

If culture is specifically requested, we will also culture the residual material but the minimum volume required would be >0.5 ml. The chances of obtaining a positive smear and culture result are increased when a large volume of CSF is submitted for examination.

Paraffin wax embedded samples are no longer accepted for processing.

Advisory service

Clinical and technical advice is available between 9am and 5pm, Monday to Friday.

Main factors affecting specimen performance

NMRS-South will endeavour to process all samples received irrespective of any delay between sample collection and arrival at NMRS-South. However, test performance, particularly of primary culture, may well be reduced by significant delays following sample collection, and we recommend service users make transport arrangements that minimise such delays.

Please make sure samples are kept at the appropriate temperature (2°C to 8°C for primary specimens and 36°C to 37°C for positive cultures) while awaiting transportation.

Note, if a specimen is submitted to NMRS-South for an investigation that we do not offer, we will temporarily archive the sample or isolate and issue a report to the sender explaining the reasons for the sample’s rejection. The specimen will then be sent back to the referring laboratory or referred on if within UKHSA Colindale.

Reference service for positive mycobacterial cultures including identification, drug resistance testing and genomic relatedness for TB

Turnaround times for bacterial identification and DSTs are dependent upon the receipt of viable, pure cultures. Cultures that are no longer viable will necessitate the sending of a second isolate, thus significantly increasing turnaround time.

Mixed or contaminated cultures in which acid-fast bacillus (AFB) has been seen require purification and subculture to obtain final results. NMRS-South will undertake such processes whenever possible rather than rejecting contaminated cultures; however, this will again result in a significantly increased turnaround time. If no AFB has been seen in the submitted culture whether contaminated or not, no further work will be carried out.

Submitting a second pure culture will often allow final results to be obtained more quickly and we always recommend that a second sample is sent when the first is mixed or contaminated.

If an aliquot of a liquid culture is to be sent then a minimum volume of a 3ml smear positive sample is required. Transfer 3ml of deposit from a settled positive sample to a sterile non-glass leak-proof universal for transport, and store the rest of the sample at your laboratory.

If a volume of between 2ml to 3ml is received, NMRS-South will attempt WGS but there will be insufficient sample volume to perform any required phenotypic testing; for this reason, we strongly advise referring laboratories to send at least 3ml. Samples of less than 2ml will be not be processed.

Solid cultures can be submitted when there is visible growth on the slope. Leaking cultures will not be processed and a report will be issued informing the user of this.

Please do not submit culture plates. These will be not be processed and a report will be issued informing the user of this.

Please do not submit Mycobacteria Growth Indicator Tubes (MGIT).

Primary service

Though NMRS-South will not reject samples that are subject to significant delay between collection and receipt, clinical specimens submitted for culture should be as fresh as possible. We strongly recommend that specimens are refrigerated if any delays in submission to NMRS-South are likely.

Do not add diluent to specimens.

Specimen requirements for microscopy and culture

Sample type	Sample volume and container	Comments and special precautions
Respiratory specimens
Sputum	Ideally, samples should be ≥5ml in volume in CE-marked leak-proof non-glass container without preservatives. Lower volumes will be accepted, but not all tests requested may be performed. This will be discussed with the laboratory before processing.	Ideally, 3 samples should be collected approximately 8 to 24 hours apart with at least one from early morning shortly after waking.
Bronchial Alveolar Lavage (BAL)/ Bronchial Washings	Ideally, samples should be ≥5ml in volume in CE-marked leak-proof non-glass container without preservatives. Lower volumes will be accepted, but not all tests requested may be performed. This will be discussed with the laboratory before processing.	Contamination of the bronchoscope with tap water, which may contain environmental Mycobacterium spp, should be avoided.
Sterile specimens
CSF, pleural fluid, aspirates, effusions, other sterile fluids	As large a volume as can be sent in a CE-marked leak-proof non-glass container without preservatives. Submit CSF samples in a sterile 60ml container where possible.	Collect aseptically. Fastrack testing requires a minimum volume of 0.5ml. With very small volumes, not all tests requested may be performed. This will be discussed with the laboratory before processing.
Blood and bone marrow	To be advised	To be advised
Skin, bone and tissue, including post mortem samples	As much as possible. CE-marked leak-proof non-glass container without preservatives.	Collect aseptically. Sterile distilled water can be added to prevent desiccation. A caseous portion should be selected if possible. Tissue biopsy specimens received in formalin are unacceptable for culture.
Endobronchial Ultrasound Bronchoscopy (EBUS)	As much as possible. CE-marked leak-proof non-glass container without preservatives.
Other specimens
Urine	Whole Early Morning Urines (EMU) in CE-marked leak-proof container that does not contain boric acid.	Direct microscopy is not performed. Should be collected in the early morning on 3 consecutive days in a CE-marked leak-proof container that does not contain boric acid. MSUs will be rejected.
Faeces	Faeces samples are only tested upon NMRS-South Consultant authorisation. Please contact NMRS-South before sending. If authorised, a maximum of 20 ml in a single container. CE-marked leak-proof non-glass container without preservatives.	Direct microscopy is not performed.
Gastric aspirates	Ideally, >5 ml in a CE-marked leak-proof non-glass container without preservatives. Smaller volumes will be accepted, however all tests requested may not be performed. This will be discussed with the laboratory before processing.	Collect samples early in the morning (before breakfast) on 3 consecutive days. Aspirates should be promptly delivered and processed to avoid acidic deterioration of organisms.
Pus and wound aspirates	As much as possible in CE-marked leak-proof non-glass container without preservatives.	Collect aseptically. Pus is the sample type of choice. Swabs will be rejected.
Specimens of non-human origin		If you wish to send samples of non-human origin please contact NMRS-South before sending.

Fastrack service

This service offers rapid molecular detection of M. tuberculosis complex and rifampicin resistance from primary specimens.

If testing is required, please make sure that samples are sent and received at NMRS-South by 9:30am for it to be included in that day’s testing.

Ideal specimens are smear positive primary respiratory specimens as these have the highest load of acid fast bacilli (AFBs); the assay sensitivity in smear negative specimens is significantly lower due to the lower bacillary load.

Sensitivity is lower again for fluid specimens, such as CSF, pleural fluid and ascitic fluid. The minimum volume of CSF (not supernatant) that can be examined is 0.5ml. The minimum volume of other fluids required is 1.0ml; however, submitting the largest possible volume of CSF and other fluids will increase the sensitivity. For respiratory specimens, at least 1ml of sample is required.

Please note that lysed blood, heavily bloodstained samples or pus containing samples can interfere with PCR based reactions. DNA in specimens requesting molecular tests may degrade if stored for too long before referral. We no longer offer this service for paraffin wax embedded samples. Urine samples have not been validated for this method.

We also offer PCR-based testing for detection of resistance to isoniazid, quinolones and aminoglycosides in primary samples under certain circumstances. Please contact NMRS-South clinicians to discuss cases where you feel this may be required.

If the sample is received and requires decontamination, this will delay PCR testing. If resistance to isoniazid, quinolones and aminglyocsides is detected, the specimen will also be cultured on solid and liquid media if this was not requested originally to maximise the detection and subsequent testing for drug-resistant tuberculosis.

Referral of specimens and cultures

No specimens or cultures are routinely referred by NMRS-South to other laboratories, except for particular MDR M.tuberculosis isolates that require testing to Bedaquiline, Clofazimine and Delamanid, which will be sent to the Emerging bacterial pathogens unit, San Raffaele Scientific Institute, Milan, Italy for testing.

In exceptional circumstances, the NMRS-South Business Continuity Plan (BCP) may be invoked and samples will need to be referred to another laboratory. Should this occur, the work shall be placed with a competent laboratory which complies with ISO15189:2012 or other accreditation standard as appropriate and NMRS-South will request assurance from the referral laboratory about quality assurance practices for monitoring purposes. If other investigations are required at another laboratory then it is strongly recommended that a further specimen or culture is sent directly to that laboratory.

Requesting additional tests

Fastrack

Additional requests for Primary Fastrack testing must be accompanied by an NMRS Fastrack request form (N2).

Requests can be processed, on receipt of sufficient and suitable material, within the time periods specified below:

• CSF samples: within one day of specimen receipt
• sterile samples (except CSF): within 2 weeks of specimen receipt
• smear negative sputum: within one day of specimen receipt
• smear positive sputum: up to one week of specimen receipt

M. tuberculosis susceptibility testing

All first isolates of M. tuberculosis have resistance prediction by WGS; phenotypic susceptibility testing is only performed for first line agents if WGS predicts resistance or fails to make a prediction.

All new multi-drug resistant isolates (MDRs) are processed for phenotypic reserve DST. Repeat phenotypic testing will only be performed on isolates received more than 2 months after previous testing.

Additional susceptibility testing on M. tuberculosis isolates must be discussed with NMRS-South before requests are submitted.

NTM susceptibility testing

The following samples will receive sensitivities as part of routine protocol:

• all sterile sites and non-pulmonary site samples
• first Mycobacterium kansasii (M. kansasii) isolates from pulmonary samples
• respiratory samples from patients with cystic fibrosis, HIV, children (aged under 16 years) and other immunosuppression

NTM isolates will be set up for an appropriate panel of phenotypic testing depending on the species based on the organism identification and the patient’s clinical status. Full and accurate completion of the request form aids in this process.

Additional susceptibility testing on NTM isolates can be requested by contacting us.

Specimen and sample submission guidelines

Specimens must be labelled with the following:

• last name and first name, or other unique patient identifier
• sender’s sample number or reference number
• date of birth

Request forms must match the corresponding specimen and include the above information on the sample as well as the following details:

• tests required
• sample type
• specimen or isolation site
• date of dispatch
• NHS number
• sex
• date and time of collection of specimen
• relevant clinical information
• reference number

The name and contact information of the requester (telephone number is vital for urgent requests) should also be included.

Request forms to accompany specimens and cultures

NMRS-South request forms are available on GOV.UK including:

• Mycobacterium referral form (N1) (primary samples and positive cultures)
• NMRS Fastrack request form (N2)

Order pre-labelled request forms with your requestor code and address from the laboratory information management system (LIMS) department via email (LimsHelpdesk@ukhsa.gov.uk). This will reduce clerical errors.

Make sure the appropriate NMRS-South request from is fully completed for the sample being submitted with the required information as stated above (under Specimen and sample submission guidelines) as well as the correct telephone number, particularly for primary Fastrack requests.

Each sample must be accompanied by an individual request from, even if more than one sample is submitted from the same patient.

The UKHSA NMRS-South laboratory advises users where forms are poorly completed and in these instances, the user will be charged. Please state clinical details when they are provided. Wherever possible, NMRS-South supports its users by not rejecting referred specimens and cultures.

The space marked ‘For NMRS-South Use Only’ is intended for use by NMRS-South staff. Please do not write in this space.

Urgent specimens

If a reference service is required urgently, please contact NMRS-South to discuss prior to dispatch. Always mark as urgent clearly on the request form.

Packaging and transport guidance

A small but significant proportion of samples received by UKHSA are poorly or inappropriately packaged. This often leads to samples leaking or being damaged during transport, therefore posing a serious risk to UKHSA staff handling them. UKHSA hopes to eliminate this risk by helping laboratories to understand basic packaging requirements.

The following guidelines are intended to cover the transport of clinical samples from humans, or cultures of micro-organisms isolated from such samples to another laboratory for diagnostic or other clinical testing within the UK where the micro-organisms suspected of causing the disease are all either hazard groups 2, 3 or 4. The terms Category A and Category B are limited to classifying samples or microbial cultures being transported to another laboratory.

These guidelines are not intended as a substitute for reading the advice given by the Department for Transport (DfT) and the Department of Health and Social Care (DHSC).

For further information, visit:

• Shipping dangerous goods on GOV.UK
• Transporting dangerous goods on GOV.UK
• International Civil Aviation Organization (ICAO) website
• United Nations Economic Commission for Europe (UNECE) website

Reporting incidents during transportation that may affect the safety of personnel

NMRS-South will report any leaking containers and improperly packaged parcels to users.

Sample description	Packaging requirement
Category A samples are known or suspected to contain a microbial agent with the following definition: “an infectious substance which is transported in a form that if exposure to it occurs, is capable of causing permanent disability, life-threatening or fatal disease to humans or animals” (see indicative list). The majority are Hazard Group 3 or 4.	Assign to UN2814 (Humans) Packaging Instructions PI620 Supporting documentation as per dangerous goods (ADR) driver certification requirements. Transport as Category A ADR certified courier.
For practical reasons to allow referral and reference services to continue, a limited number of Category A agents have exempted from being transported as Category A. These are: • Vero-cytotoxin producing Escherichia coli (VTEC) • M. tuberculosis • Shigella dysenteriae type 1	Assign UN3373 Packaging instruction PI650. Send by courier – Royal Mail will not accept.
Category B samples are those that do not meet the definitions of Category A.	Assign UN3373 Packaging instruction P1650. Send by post or courier – Royal Mail will accept.

Leaking cultures will not be processed by NMRS-South. Users will be informed and a repeat sample requested.

NMRS-South will endeavour to process primary material if leakage occurs. However, this is likely to compromise the chance of successful culture and we will request the user to send us an additional specimen.

Repeated offences may be escalated to the UKHSA corporate health and safety department.

Packaging guidance

Label the specimen or culture bottle with the name of the patient (or unique identifier) and the laboratory number. All specimens and cultures sent to NMRS-South must be packed in accordance with IATA regulations 650/602.

Figure 1: Packaging requirements for dispatch to NMRS-South

The packaging should consist of 4 components:

• a leak-proof primary receptacle
• a polythene bag containing absorbent material
• a leak-proof secondary packaging
• an outer packaging of adequate strength

For liquids, each leak-proof primary receptacle should be wrapped in absorbent material sufficient to absorb all contents of the sample and placed inside a polythene bag. There should be one sample per bag. The use of parafilm is not recommended.

The bagged samples may then be placed together inside a rigid, leak-proof plastic container. This container is placed inside a fibreboard box or approved DX plastic outer packaging. This outer packaging should be of sufficient size for its capacity, mass and intended use, and with at least one surface having minimum dimensions of 100mm by 100mm.

Documentation must be placed between the secondary container and the outer packaging. Do not place it inside the plastic container.

Do not submit positive cultures on agar plates. These will be discarded and not processed.

Specimens sent by Royal Mail or courier

To minimise delays, we recommend specimens, especially those sent for our Fastrack molecular diagnostic service, are sent by routine courier, for example DX or other specialised courier.

Please make sure that the courier is able to reach NMRS-South before 5pm.

Cultures can only be sent by courier.

Reports

NMRS-South issues acknowledgement of receipt reports on the date of receipt of the samples.

NMRS-South reports are routinely sent out via LabPortal. Printed reports will only be sent out if the referring laboratory is not registered to PHE-eLab. For details on how to register and further information, please email LimsHelpdesk@ukhsa.gov.uk

Users can access archived reports on PHE-eLab using the search function for up to 2 years.

It is our policy that reports containing patient data should not be sent by routine email.

Emails cannot be relied on to guarantee security of patient data because they can be intercepted by a third party on route, unless encrypted.

Quality assurance

NMRS-South is accredited in accordance with International Standard ISO15189:2012 – Medical Laboratories with Laboratory No.10080.

All tests are in scope with the exception of:

• WGS for genotypic predictions to Ethambutol, Pyrazinamide, Aminoglycosides, Fluoroquinolones and Streptomycin
• processing non-pulmonary samples for Fastrack analysis
• phenotypic pyrazinamide susceptibility testing on liquid culture
• all test procedures associated with animal samples

View the certificate of accreditation and schedule of accreditation for NMRS-South, issued by the UK Accreditation Service (UKAS).

NMRS-South participates in numerous EQA schemes, including those run by:

• UK National External Quality Assurance Scheme (NEQAS)
• WHO
• INSTAND

The quality of our systems is also checked by our Internal Quality Assurance (IQA) schemes, which requires selection of referred samples for ‘blinded’ testing at a later date. After processing, the results for IQA samples are ‘unblinded’ and are assessed against the results originally reported to the sending laboratory. Any discrepancies are fully investigated as to their root cause before remedial action is implemented.

Any discrepancies leading from EQA or IQA are fully investigated as to their root cause before corrective action is implemented. Results of our EQA and IQA performance are discussed at departmental meetings as appropriate.

Tissue samples from deceased people

Compliance with the Human Tissue Act

The UKHSA Microbiology Services is licensed by the Human Tissue Authority (HTA) (licence number 12459) to store tissues from deceased people for scheduled purposes. Post mortem samples are submitted to UKHSA by coroners or pathologists for examination to help them determine the cause of death.

As part of our public health remit, we sometimes need to retain these samples for the purpose of public health monitoring, which is defined as a scheduled purpose within the Human Tissue Act 2004. Further analysis of these samples may help determine the cause of an outbreak due to an infectious disease or may allow identification of new strains of infectious agents at a later date.

Obtaining consent to remove, store and use human tissues for a scheduled purpose is one of the underlying principles of the Human Tissue Act. UKHSA Microbiology Services receives post-mortem samples from coroners’ post-mortems or from NHS establishments across the UK and therefore we are not in a position to either seek consent ourselves or have arrangements in place to confirm that the requirements of the Act have been complied with by the sender.

We would ask coroners and pathologists who send post mortem samples to UKHSA Microbiology Services to provide us with details of consent, and would also ask that consent includes retention of the samples for the purpose of public health monitoring.

When tissue samples from deceased people are received at the UKHSA Microbiology Services. They are retained securely and confidentiality is maintained in compliance with Caldicott principles as are all samples received at this centre.

It is normal practice for tissue samples from the deceased to be disposed of in the same way that all other clinical samples we receive are disposed of. However, we will adhere to any specific requirements regarding disposal or returning tissue samples if requested by the sending coroner or pathologist.

UKHSA recognition of Caldicott recommendations

The recommendations of the Caldicott report (1997) and the subsequent Information Governance Review (2013) have been adopted by UKHSA as a whole. These recommendations relate to the security of Patient Identifiable Data (PID) and the uses to which they are put.

NMRS-South observes Caldicott guidance in handling PID. The Clinical Lead of NMRS-South and others are advised on confidentiality issues and for the monitoring the physical security of PID in all parts of the NMRS-South site. This also applies to the transfer of results of investigations to and from the site whether by mail services, electronically or by telephone. The value of ‘safe haven’ arrangements, or other means by which the sender and receiver of information can identify themselves to each other before data is transferred, is emphasised. See the reports section of this user manual.

NMRS-South audits the security of its PID in collaboration with its customers. Customers are invited to review our arrangements in conjunction with individual laboratory directors and/or the UKHSA Caldicott Guardian. Customers are also asked to draw to the Caldicott Guardian’s attention any instances where PID security has been threatened or has broken down.

Any uses that PID are put to outside the clinical diagnostic services generally allow patient identifiers to have been removed beforehand, and when PID is used for research purposes the proposals are considered first by the appropriate Ethics Committee. All enquiries regarding the security and use of PID should be addressed to the Laboratory Manager at nmrs.south@ukhsa.gov.uk